Benedetta di Robilant co-founded Dorian Therapeutics in 2018 where she operates as the Chief Scientific Officer. 

​

Before founding Dorian, Benedetta joined Stanford University at the Institute for Stem Cell Biology and Regenerative Medicine (ISCBRM) as a postdoctoral fellow. She worked on self-renewal and cellular senescence in normal aging and age-related diseases, including cancer, Down syndrome and Alzheimer’s disease. 

​

Benedetta holds a M.S. in Medical, Molecular and Cellular Biotechnology and a Ph.D. in immuno-oncology from the San Raffaele University (Milan, Italy), where she focused on adoptive immunotherapy and CAR-T cells therapies.

​

Benedetta is author of several scientific publications in top tier journals and she is an inventor on U.S. patents.